
Novavax COVID-19 vaccine proves effective in trials
In a U.K trial, the drug proved 96 percent efficacy against the original strain of COVID-19.
Novavax has announced its COVID-19 vaccine, NVX-CoV2373, proved very effective in guarding against the disease.
According to
"We are very encouraged by the data showing that NVX-CoV2373 not only provided complete protection against the most severe forms of disease, but also dramatically reduced mild and moderate disease across both trials," Stanley C. Erck, president and CEO of Novavax, says in the release. “Importantly, both studies confirmed efficacy against the variant strains. Today marks one year since the WHO officially declared the COVID-19 pandemic, and with this data in hand, we are even more motivated to advance our vaccine as a potential weapon in the fight to end the suffering caused by COVID-19."
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.